PURPOSE OF REVIEW: Recently, initial studies have been carried out in patients using monocyte chemoattractant protein-1 (MCP-1) inhibitors. This review summarizes the known function of MCP-1 in regulating monocytes during inflammation and its role in inflammatory disease of the kidney. RECENT FINDINGS: MCP-1 is one of the first chemokines described and plays an important role in renal inflammatory disease. The function of MCP-1 has been investigated and analyzed in both animal models of renal disease and renal patients. MCP-1 mediates firstly the release of monocytes from the bone marrow, and then generates a gradient in the endothelial glycocalyx to direct monocytes to sites of inflammation, thereby alleviating the migration of blood leukocytes into the inflamed tissue. In addition, MCP-1 has direct signaling effects in monocytes and influences migration, proliferation, and differentiation of leukocytes. Blockade of MCP-1 in several models of renal disease has ameliorated the disease, suggesting that inhibition of MCP-1 is a promising and valid strategy to treat patients with renal inflammatory disease. SUMMARY: Understanding the role of MCP-1 in monocyte homeostasis and the implications of MCP-1 inhibition in renal disease will help in designing better diagnostic and therapeutic strategies in patients with inflammatory renal disease.
PURPOSE OF REVIEW: Recently, initial studies have been carried out in patients using monocyte chemoattractant protein-1 (MCP-1) inhibitors. This review summarizes the known function of MCP-1 in regulating monocytes during inflammation and its role in inflammatory disease of the kidney. RECENT FINDINGS:MCP-1 is one of the first chemokines described and plays an important role in renal inflammatory disease. The function of MCP-1 has been investigated and analyzed in both animal models of renal disease and renalpatients. MCP-1 mediates firstly the release of monocytes from the bone marrow, and then generates a gradient in the endothelial glycocalyx to direct monocytes to sites of inflammation, thereby alleviating the migration of blood leukocytes into the inflamed tissue. In addition, MCP-1 has direct signaling effects in monocytes and influences migration, proliferation, and differentiation of leukocytes. Blockade of MCP-1 in several models of renal disease has ameliorated the disease, suggesting that inhibition of MCP-1 is a promising and valid strategy to treat patients with renal inflammatory disease. SUMMARY: Understanding the role of MCP-1 in monocyte homeostasis and the implications of MCP-1 inhibition in renal disease will help in designing better diagnostic and therapeutic strategies in patients with inflammatory renal disease.
Authors: Gaia M Coppock; Lillian R Aronson; Jihwan Park; Chengxiang Qiu; Jeongho Park; Jonathan H DeLong; Enrico Radaelli; Katalin Suszták; Christopher A Hunter Journal: J Immunol Date: 2020-06-10 Impact factor: 5.422
Authors: Robin S Chirackal; Muthuvel Jayachandran; Xiangling Wang; Samuel Edeh; Zejfa Haskic; Majuran Perinpam; Timothy M Halling; Ramila Mehta; Marcelino E Rivera; John C Lieske Journal: Am J Physiol Renal Physiol Date: 2019-08-28
Authors: Dennis G Moledina; Selin Isguven; Eric McArthur; Heather Thiessen-Philbrook; Amit X Garg; Michael Shlipak; Richard Whitlock; Peter A Kavsak; Steven G Coca; Chirag R Parikh Journal: Ann Thorac Surg Date: 2017-02-21 Impact factor: 4.330
Authors: José de Oliveira Vilar Neto; Carlos Alberto da Silva; Gdayllon Cavalcante Meneses; Daniel Vieira Pinto; Luciana Catunda Brito; Said Goncalves da Cruz Fonseca; Renata de Sousa Alves; Alice Maria Costa Martins; Cláudio de Oliveira Assumpção; Elizabeth De Francesco Daher Journal: Toxicol Res (Camb) Date: 2020-05-13 Impact factor: 3.524
Authors: Payel Sen; Alexandra Helmke; Chieh Ming Liao; Inga Sörensen-Zender; Song Rong; Jan-Hinrich Bräsen; Anette Melk; Hermann Haller; Sibylle von Vietinghoff; Roland Schmitt Journal: J Am Soc Nephrol Date: 2020-03-24 Impact factor: 10.121